The announcement comes a day after the drugmaker started testing its
rheumatoid arthritis drug, Kevzara, with partner Sanofi against the
Regeneron said it will select the top two antibodies to develop a
'cocktail' treatment, which the company is looking to manufacture on
a large scale by mid-April.
The company said it was working to make smaller quantities available
for initial testing and produce hundreds of thousands of doses per
month by the end of summer.
[to top of second column]
The efforts are a part of the company's partnership with the U.S. Department of
Health and Human Services to develop a coronavirus treatment.
Regeneron also said it was working with the U.S. Biomedical Advanced Research
and Defense Authority to further increase its manufacturing capacity.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
[© 2020 Thomson Reuters. All rights
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.